Description: bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated Identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL Rapid AST system; ETEST Gradient method on culture media; BIOMERIEUX EPISEQ CS whole genome sequencing solution for epidemiologic monitoring; and VIDASB·R·A·H·M·S PCTTM, a specific marker of severe bacterial infections/sepsis. It also provides Biomérieux vision suite, a software that provides actionable information to support diagnosis and clinical decision making; culture media and associated instruments; ARGENE Monoplex PCR tests; NUCLISENS ranges, a product for automation of the molecular biology laboratory and extraction; EMAG system For DNA and RNA extraction; ESTREAM, an automated preparation station for samples to process PCR tests; GENE-UP and VERIFLOW ranges for detection of microorganisms for the food industry. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Home Page: www.biomerieux.com
376 Chemin De l’Orme
Marcy-l'Étoile,
69280
France
Phone:
33 4 78 87 20 00
Officers
| Name | Title |
|---|---|
| Mr. Pierre Boulud | Chief Executive Officer |
| Mr. Guillaume Bouhours | Executive VP of Purchasing and Information Systems & CFO |
| Sylvain Morgeau | Investor Relations |
| Ms. Audrey Dauvet | Executive Vice President of Legal, Corporate Integrity & Public Affairs |
| Ms. Valerie Leylde | Executive Vice President of Human Resources, Communications & CSR |
| Mr. Pierre Charbonnier | Executive Vice President of Global Quality, Manufacturing & Supply Chain |
| Mr. Yasha Mitrotti | Executive Vice President of Industrial Applications |
| Mr. Frederic Beseme | Head of CSR |
| Jennifer Zinn | Executive Vice President of Clinical Operations |
| Dr. Charles K. Cooper | Executive VP & Chief Medical Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 19.8807 |
|---|---|
| Trailing PE: | 27.9971 |
| Price-to-Book MRQ: | 2.9621 |
| Price-to-Sales TTM: | 3.0253 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 13409 |